Forbes A pill to prevent dengue fever—a viral infection also called “breakbone fever” for the severe pain it can cause—could be on the horizon, according to data presented by Johnson & Johnson on Friday, promising news that could signal a future treatment against what experts warn is a pressing and growing health threat that could soon return to plague the United States.
An antiviral pill developed by pharma giant Johnson & Johnson appeared to protect people against dengue when exposed to a virus that causes the disease, according to early data from the company’s clinical trial presented at the American Society of Tropical Medicine & Hygiene Annual Meeting in Chicago.
The trial involved healthy volunteers taking the drug—called JNJ-1802—or an inert placebo for 26 days and being injected on day five with a type of dengue virus, a type of study known as a challenge trial.
Fair Use Notice
UNMC Global Center for Health Security staff curate publicly available news and information for educational and informational purposes. Brief excerpts of published articles may be displayed under principles of Fair Use, with credit and links provided to the source publications. All copyrights remain the property of their respective owners.